MedTrace Logo

Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease

NCT04713982 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-14

No results posted yet for this study

Summary

Examine the effects of deutetrabenazine on functional speech and gait impairment

Conditions

  • Huntington Disease

Interventions

DRUG

Deutetrabenazine

Maximum dose of 48mg/day or up to 36 mg/d if receiving a strong CYP2D6 inhibitor

Sponsors & Collaborators

  • Vanderbilt University Medical Center

    lead OTHER

  • Teva Branded Pharmaceutical Products R&D, Inc.

    collaborator INDUSTRY

Principal Investigators

  • Amy E Brown, MD · Vanderbilt University Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-19
Primary Completion
2026-06-30
Completion
2026-10-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04713982 on ClinicalTrials.gov